OrsoMedical

Privacy Policy

Last Updated: November 19, 2026

1. Introduction

OrsoMedical ("we," "us," or "our") operates a fee-for-service medical information platform that provides AI-generated health information with optional licensed physician review. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you use our services.

IMPORTANT: Our service is designed for de-identified health questions only — please leave names, dates of birth and other identifiers out of your question text. Your questions are stored with your account and email address. You should NOT submit any personally identifiable health information (PHI) or protected health information.

2. Information We Collect

2.1 Information You Provide

  • Account Information: Email address and password when you create an account.
  • Health Questions: The medical questions you submit through our platform. These should be de-identified and contain no personal health information.
  • Payment Information: When you purchase services, payment is processed through Stripe. We do not store your full credit card information.

2.2 Information Automatically Collected

  • Device and browser information
  • IP address and browser information, stored with your questions and consent records for security, fraud prevention and record-keeping
  • Usage data and interaction with our services
  • Cookies and similar tracking technologies

3. De-Identified Questions Policy

Critical Privacy Requirement

You must NOT include any of the following in your questions:

  • Names (yours or others)
  • Dates of birth or ages that could identify you
  • Addresses or location information
  • Phone numbers or email addresses
  • Medical record numbers
  • Social Security numbers
  • Insurance information
  • Any other personally identifiable information

By submitting a question, you certify that it contains no personally identifiable information. If we identify identifying personal health information in your submission, we may decline or remove the question; any fee for a physician review that was not delivered is refunded.

4. How We Use Your Information

  • To provide and maintain our services
  • To process your questions and generate AI responses
  • To facilitate physician review of questions (for paid services)
  • To process payments and send transaction confirmations
  • To communicate with you about your account or services
  • To improve and optimize our services
  • To comply with legal obligations

5. AI Processing

Your de-identified questions are processed by artificial intelligence systems to generate initial responses. These AI systems are trained on medical literature and general health information. AI responses are:

  • Generated automatically based on your question
  • Not reviewed by a physician unless you purchase a physician review service
  • For educational and informational purposes only
  • Not a substitute for professional medical advice

6. Data Sharing and Disclosure

We may share your information with:

  • Service Providers: Third parties that help us operate our services (payment processors, hosting providers, AI services)
  • Physicians: Licensed physicians who review questions (for paid physician review services)
  • Legal Requirements: When required by law or to protect our rights

We do NOT sell your personal information to third parties. We do not sell, rent, lease, or share your mobile phone number, SMS opt-in information, or messaging consent with any third parties or affiliates for marketing or promotional purposes. The service-provider sharing described above never includes text-messaging opt-in data or consent (see Section 11).

7. Data Security

We implement appropriate technical and organizational measures to protect your information, including:

  • Encryption of data in transit and at rest
  • Secure authentication systems
  • Regular security assessments
  • Limited access to personal information

8. Data Retention

We retain your information for as long as necessary to provide our services and comply with legal obligations. De-identified questions and responses may be retained indefinitely for service improvement purposes. You may request deletion of your account and associated data by contacting us.

9. Your Rights

Depending on your location, you may have the right to:

  • Access your personal information
  • Correct inaccurate information
  • Delete your information
  • Opt out of certain data uses
  • Data portability

10. HIPAA Notice

OrsoMedical is NOT a covered entity under HIPAA. Our service is designed for de-identified, educational health questions only. We do not provide medical treatment, diagnose conditions, or maintain medical records. No doctor-patient relationship is created through use of our services.

11. SMS / Text Messaging Program

OrsoMedical offers an optional SMS/text message program to users who opt in. The program sends account and service notifications, appointment and visit reminders, and order or result-ready alerts.

  • Opt-in: You consent to receive text messages by providing your mobile number and checking the SMS consent box when you create an account or request services. Consent to receive text messages is not a condition of any purchase.
  • Message frequency: Message frequency varies.
  • Message and data rates: Message and data rates may apply.
  • Help and opt-out: Reply HELP for help or STOP to unsubscribe at any time. After you reply STOP you receive one confirmation message and no further messages.

No mobile information will be shared with third parties or affiliates for marketing or promotional purposes. Text messaging originator opt-in data and consent are not shared with any third parties or affiliates, and are excluded from every category of information sharing described in Section 6 of this Privacy Policy. Mobile information may be disclosed only to subcontractors that provide services in direct support of the messaging program (for example, our SMS delivery provider), solely for that purpose.

For the full program terms, see our SMS Terms.

12. Contact Us

If you have questions about this Privacy Policy or our data practices, please contact us at:

OrsoMedical
Email: privacy@orsomedical.com

13. Changes to This Policy

We may update this Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page and updating the "Last Updated" date.

Latest
●GLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJM●Ashwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.com●Ferrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASH●Lion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMed●NMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJM●Resistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSM●Sage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-Analysis●Berberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP Journals●Vitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODS●Fisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMed●GLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJM●Ashwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.com●Ferrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASH●Lion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMed●NMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJM●Resistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSM●Sage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-Analysis●Berberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP Journals●Vitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODS●Fisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMed